RGC (Regencell Bioscience Holdings) EPS without NRI: $-0.02 (TTM As of Dec. 2025)


RGC Regencell Bioscience Holdings Ltd RGC
34 GF Score
Price $7.99
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings EPS without NRI?

Regencell Bioscience Holdings RGC +31.21% 34 EPS without NRI is $-0.02 as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 787 Drug Manufacturers companies, Regencell Bioscience Holdings ranks better than 68.49% on this metric.

Regencell Bioscience Holdings's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 22.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Regencell Bioscience Holdings's EPS without NRI or its related term are showing as below:

RGC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -146.6   Med: -62.95   Max: 22.4
Current: 22.4

During the past 7 years, Regencell Bioscience Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 22.40% per year. The lowest was -146.60% per year. And the median was -62.95% per year.

RGC's 3-Year EPS without NRI Growth Rate is ranked better than
68.49% of 787 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs RGC: 22.40

Regencell Bioscience Holdings's EPS (Diluted) for the six months ended in Dec. 2025 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.

Regencell Bioscience Holdings's EPS (Basic) for the six months ended in Dec. 2025 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.


Regencell Bioscience Holdings  (NAS:RGC) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Regencell Bioscience Holdings EPS without NRI Related Terms


Regencell Bioscience Holdings EPS without NRI Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings EPS without NRI Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS without NRI
Get a 7-Day Free Trial -0.00 -0.02 -0.01 -0.01 -0.01

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 -0.00 -0.00 -0.01

RGC vs SUPN, BCRX, PBH: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's PE Ratio without NRI falls into.


RGC
34GF Score
Regencell Bioscience Holdings Ltd RGC
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.02 mean?
Regencell Bioscience Holdings (RGC) has a EPS without NRI of $-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Regencell Bioscience Holdings and its competitors. According to the industry distribution chart, Regencell Bioscience Holdings ranks #248 out of 787 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Regencell Bioscience Holdings' EPS without NRI too high?
Regencell Bioscience Holdings' current EPS without NRI is $-0.02. Based on the distribution chart, Regencell Bioscience Holdings ranks #248 out of 787 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Regencell Bioscience Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' EPS without NRI compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #248 out of 787 companies for EPS without NRI. This puts Regencell Bioscience Holdings in the upper half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current EPS without NRI is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current EPS without NRI of $-0.02. The current EPS without NRI is $-0.02. Regencell Bioscience Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current EPS without NRI is $-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
34GF Score

Get the complete analysis for RGC

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.99
Price